BioVaxys Technology Corp.
BVAXF
$0.0321
$0.003512.24%
OTC PK
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -28.72% | 86.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.67% | 86.33% | |||
| Operating Income | 26.67% | -86.33% | |||
| Income Before Tax | 62.53% | -131.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 62.53% | -131.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 62.53% | -131.93% | |||
| EBIT | 26.67% | -86.33% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 65.06% | -112.82% | |||
| Normalized Basic EPS | 25.00% | -47.37% | |||
| EPS Diluted | 65.06% | -112.82% | |||
| Normalized Diluted EPS | 25.00% | -47.37% | |||
| Average Basic Shares Outstanding | 8.11% | 10.22% | |||
| Average Diluted Shares Outstanding | 8.11% | 10.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||